Iridex (IRIX) Q1 2026 earnings review
Top-Line Reverses as Retina Falters, But Profitability Story Survives
Iridex's four-quarter streak of revenue growth is over. Sales slipped 1% YoY to $11.8M, completely dragged down by a 12% revenue drop in the Retina segment due to international supply constraints. Despite this top-line shock, management successfully protected the bottom line. Operating expenses dropped another 4% YoY, keeping Adjusted EBITDA positive ($0.3M). While the cost-cutting narrative is stable, a $1.4M cash burn leaves the company with just $4.6M in the bank, making the execution of their FY26 cash-flow positive guidance absolutely critical with zero margin for error.
🐂 Bull Case
The Cyclo G6 franchise is accelerating, growing 14% YoY driven by robust probe sales (15,500 units). The recurring revenue model here is highly resilient.
Management continues to deliver on cost discipline. Operating expenses fell 4% YoY to $5.1M, proving that the lean structure achieved in FY25 is sustainable.
🐻 Bear Case
The Retina segment went from 22% growth in Q4 to a 12% contraction in Q1. International regulatory red tape and supply constraints are stifling their flagship PASCAL sales.
Cash dropped to $4.6M. Even with expected Q1 seasonality, the company is operating on a razor-thin cash margin and remains highly sensitive to any further revenue misses.
⚖️ Verdict: ⚪
Neutral. The company proved it can defend its bottom line even when revenue misses expectations, but a shrinking top line and a fragile balance sheet limit any aggressive upside.
Key Themes
The Tariff Contradiction: Shield Turned Vulnerability
A massive red flag emerged regarding the macro supply chain narrative. In 25Q1, management explicitly stated their U.S.-based manufacturing provided a 'competitive shield' with 'minimal direct exposure' to tariffs. Fast forward to 26Q1, and management is directly blaming a gross margin decline on 'increased product costs related to recent tariff developments' as they transition to contract manufacturers. This directly contradicts their positive prior narrative and highlights severe execution risk in their margin-improvement strategy.
Retina Segment Reversing Course
The Retina business completely stalled, reversing from 22% growth in 25Q4 to a 12% contraction in 26Q1 ($5.8M). Management cited international supply constraints and delayed regulatory approvals. This lagging segment is a major concern as it single-handedly erased the strong double-digit growth seen in the Glaucoma division.
Cyclo G6 Delivering Consistent Acceleration
The Glaucoma segment is the lone growth engine. Cyclo G6 product revenue accelerated 14% YoY to $3.6M, driven by 15,500 disposable probe sales. The strategy of leveraging the MicroPulse technology installed base and utilizing software tools like MedScout to drive recurring consumable revenue is proving highly effective.
Cost Optimization Protecting the Bottom Line
Operating expenses were $5.1M, a 4% YoY reduction. Management is successfully holding the line on general and administrative costs. This discipline is the sole driver keeping Adjusted EBITDA in positive territory.
Cash Buffer is Dangerously Thin
Cash and equivalents fell $1.4M to end the quarter at just $4.6M. While management notes that Q1 is historically the highest cash-usage quarter due to annual compensation payments, a $4.6M balance leaves virtually no shock absorber for unexpected macro headwinds or further supply chain snags.
Contract Manufacturing Transition
Despite the short-term margin hit from tariffs, the company is continuing a multi-year transition of production to lower-cost, third-party contract manufacturers. This remains the primary long-term driver for projected gross margin expansion, expected to fully materialize across 2026 and 2027.
Other KPIs
Stable sequentially compared to 25Q4 (37%), but decelerating from 43% in the prior year period. The YoY compression reflects the friction costs of shifting to lower-cost contract manufacturers combined with unexpected tariff impacts.
Decelerating slightly from $0.4 million a year ago, but keeping the company in positive territory. Given the revenue miss, printing a positive EBITDA number validates the resilience of the new operating structure.
Guidance
Stable to Decelerating. Reaffirmed. The midpoint of $52M implies a slight YoY decline (-1.3%) from FY25's $52.7M. This incorporates the total exclusion of Middle East sales due to geopolitical conflict, shifting the burden entirely to U.S. and unaffected international markets.
Accelerating cost discipline. The midpoint implies quarterly OpEx of roughly $4.75M for the remainder of the year, which requires the company to make further cuts from Q1's $5.1M run rate.
Accelerating. Management expects cash generation to improve sequentially in Q2-Q4, fully offsetting the $1.4M burned in Q1. Given the tight balance sheet, achieving this is make-or-break.
Key Questions
The Tariff Narrative Reversal
Last year, you claimed domestic manufacturing provided a 'competitive shield' against tariffs. This quarter, you blamed tariffs for margin compression. What exactly changed in your supply chain to create this sudden vulnerability?
Retina Regulatory Timeline
With Retina sales falling 12% due to international supply and regulatory bottlenecks, when exactly do you expect the MDR certifications to clear in Europe to unblock this revenue?
Contingency Capital Plans
Cash is down to $4.6 million. If Q2 does not swing to positive cash generation as modeled, do you have contingency plans for a capital raise, or are further immediate headcount reductions the only lever left?